Scilex Holding Company

Scilex Holding Company

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
Sponsored
Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.
Sponsored
Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)
Sponsored
Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®
Sponsored
Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.
Sponsored
Scilex Holding Company Sends Letters To The U.S. Securities And Exchange Commission And Financial Industry Regulatory Authority Regarding Illegal Market Manipulation Of The Common Stock Of Scilex Holding Company
Sponsored
Scilex Holding Company Announces It Has Been Added To The MSCI Global Microcap Index
Sponsored
Scilex Holding Company Announces Final Court Approval Of A Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit Relating To Scilex's Intent To Expand The Label For Its FDA-Approved Liquid Colchicine Product, Gloperba®
Sponsored
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Sponsored
Scilex Holding Announces Issuance Of Halal Certification For Its ZTlido® Product By Circle H International, Inc.
Sponsored
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered Into A Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To The Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement
Sponsored
Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba®, Its First And Only Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024
Sponsored
Scilex Holding Company Announces That The Official Committee Of Unsecured Creditors Of Sorrento Therapeutics, Inc., Has Filed A Motion With The U.S. Bankruptcy Court To Extend The Lockup Period On Shares Of Scilex Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend From March 31, 2024 To September 30, 2024
Sponsored
Scilex Holding Company Announces $10 Million Bought Deal Offering
Sponsored
Scilex Holding Company Announces Major Initiative With A Leading National Pharmacy Chain To Stock GLOPERBA® In Most Of Their Stores Throughout the U.S.
Sponsored
Scilex Holding Company Announces Acceptance Of Abstract For Poster And Oral Presentation At The Annual Meeting Of The American Academy Of Pain Medicine (AAPM)
Sponsored
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters Into A Term Sheet With Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Sponsored
Scilex Holding Company Announces That ZTlido® Achieves A Major Milestone - Over One Million Patients Treated Since Its Launch - And Two Additional Milestones Met
Sponsored